Volume 22, Issue 4, 2022
Mesenchymal Epithelial Transition (MET): A Key Player in Chemotherapy Resistance and an Emerging Target for Potentiating Cancer Immunotherapy
Pp: 269-285
Author(s): Kenneth K.W. To* and William C.S. Cho
DOI: 10.2174/1568009622666220307105107
Published on: 01 April, 2022
Advancement and Strategies for the Development of Peptide-drug Conjugates: Pharmacokinetic Modulation, Role and Clinical Evidence against Cancer Management
Pp: 286-311
Author(s): Rishabha Malviya*, Swati Verma and Sonali Sundram
DOI: 10.2174/1568009621666211118111506
Published on: 20 January, 2022
Antibody-drug Conjugate PCMC1D3-Duocarmycin SA as a Novel Therapeutic Entity for Targeted Treatment of Cancers Aberrantly Expressing MET Receptor Tyrosine Kinase
Pp: 312-327
Author(s): Rachel Hudson, Hang-Ping Yao*, Sreedhar Reddy Suthe, Dhavalkumar Patel and Ming-Hai Wang*
DOI: 10.2174/1568009621666211222154129
Published on: 20 January, 2022
ND-16: A Novel Compound for Inhibiting the Growth of Cutaneous T Cell Lymphoma by Targeting JAK2
Pp: 328-339
Author(s): Man Zhu, Yanhong Liu, Panpan Lei, Xianpeng Shi, Wenjuan Tang, Xiaoyue Huang, Xiaoyan Pan, Cheng Wang and Weina Ma*
DOI: 10.2174/1568009622666220225121009
Published on: 10 March, 2022
Systematic Analysis of the Expression Profile and Prognostic Significance of the IGF2BP Family in Lung Adenocarcinoma
Pp: 340-350
Author(s): Zimo Zhou, Tiantong Zhu, Senxiang Chen, Sen Qin, Ying Huang* and Da Liu*
DOI: 10.2174/1568009622666220301145013
Published on: 30 March, 2022
